跳至主導覽
跳至搜尋
跳過主要內容
國立陽明交通大學研發優勢分析平台 首頁
English
中文
首頁
人員
單位
研究成果
計畫
獎項
活動
貴重儀器
影響
按專業知識、姓名或所屬機構搜尋
Reversible cerebral vasoconstriction syndrome: An under-recognized clinical emergency
Shih Pin Chen
, Jong Ling Fuh,
Shuu Jiun Wang
*
*
此作品的通信作者
臨床醫學研究所
醫學系
研究成果
:
Review article
›
同行評審
85
引文 斯高帕斯(Scopus)
總覽
指紋
指紋
深入研究「Reversible cerebral vasoconstriction syndrome: An under-recognized clinical emergency」主題。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Keyphrases
Reversible Cerebral Vasoconstriction Syndrome
100%
Thunderclap Headache
42%
Headache Attacks
28%
Pathophysiology
14%
Magnetic Resonance Imaging
14%
Effective Treatment
14%
Recurring
14%
Sympathetic Hyperactivity
14%
Angiography
14%
Ischemic Stroke
14%
Pediatric Patients
14%
Intracerebral Hemorrhage
14%
Mean Flow Velocity
14%
Vasoconstriction
14%
Middle Cerebral Artery
14%
Possible Complications
14%
Subarachnoid Hemorrhage
14%
Transcranial Color-coded Sonography
14%
Posterior Reversible Encephalopathy Syndrome
14%
Reversible Cerebral Vasoconstriction
14%
Lumbar Puncture
14%
Severe Cases
14%
Calcium Channel Blockers
14%
Catheter Angiography
14%
Middle-aged Women
14%
Nimodipine
14%
Intra-arterial Therapy
14%
Aneurysmal Subarachnoid Hemorrhage (aSAH)
14%
Venography
14%
Blood Pressure Surge
14%
Ischemic Complication
14%
Open-label Trial
14%
Neuroscience
Headache
100%
Subarachnoid Hemorrhage
50%
Angiography
50%
Magnetic Resonance Imaging
25%
Middle Cerebral Artery
25%
Brain Ischemia
25%
Hyperactivity
25%
Ultrasonography
25%
Lumbar Puncture
25%
Cerebral Hemorrhage
25%
Vasoactive
25%
Open-Label Trial
25%
Brain Disease
25%
Calcium Channel Blocker
25%
Nimodipine
25%
Medicine and Dentistry
Reversible Cerebral Vasoconstriction Syndrome
100%
Thunderclap Headache
42%
Vasoconstriction
28%
Subarachnoid Hemorrhage
28%
Pathophysiology
14%
Echography
14%
Blood Pressure
14%
Middle Age
14%
Sequela
14%
Brain Ischemia
14%
Angiography
14%
Pediatrics Patient
14%
Cerebral Hemorrhage
14%
Middle Cerebral Artery
14%
Hyperactivity
14%
Headache
14%
Lumbar Puncture
14%
Calcium Channel Blocking Agent
14%
Nimodipine
14%
Posterior Reversible Encephalopathy Syndrome
14%
Venography
14%
Intraarterial Drug Administration
14%
Conventional Angiography
14%
Vasoactive Agent
14%
Open-Label Trial
14%